Compositions and methods for improving memory, cognitive performance, providing neuroprotection, and treating neurological disease or symptoms thereof are described. The compositions comprise a synergistic combination of purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil, and preferably Blueberry Extract, and may be administered as a dietary supplement.

Compositions and methods for improving memory, cognitive performance, providing neuroprotection, and treating neurological disease or symptoms thereof are described. The compositions comprise a synergistic combination of purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil, and preferably Blueberry Extract, and may be administered as a dietary supplement.

Compositions and methods for improving memory, cognitive performance, providing neuroprotection, and treating neurological disease or symptoms thereof are described. The compositions comprise a synergistic combination of purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil, and preferably Blueberry Extract, and may be administered as a dietary supplement.

The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, calcarea fluorica, thiosinaminum, hydrastis, arctium lappa, gallium aparine, urtica urens, aloe, graphite, petroleum or a synergistic combination thereof.

The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, calcarea fluorica, thiosinaminum, hydrastis, arctium lappa, gallium aparine, urtica urens, aloe, graphite, petroleum or a synergistic combination thereof.

The present invention relates to one or more arylnaphthalene lignan(s), in particular, comfreyn A, and a pharmaceutic composition comprising it. Comfreyn A was isolated from a preparation of comfrey (Symphytum officinale L.) roots and was found to reduce inflammation by interfering with pro-inflammatory gene expression. In particular, it inhibited E-selectine expression in interleukin 1β (IL-1β)-induced HUVEC cells.

The present invention relates to one or more arylnaphthalene lignan(s), in particular, comfreyn A, and a pharmaceutic composition comprising it. Comfreyn A was isolated from a preparation of comfrey (Symphytum officinale L.) roots and was found to reduce inflammation by interfering with pro-inflammatory gene expression. In particular, it inhibited E-selectine expression in interleukin 1β (IL-1β)-induced HUVEC cells.

The present invention provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof and (ii) a penetration enhancer, and optionally including tannic acid, or an analogue or derivative thereof. The present invention also provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof, and (ii) tannic acid, or an analogue or derivative thereof, optionally including a penetration enhancer. Also provided are kits and methods of prophylactic or therapeutic treatment of inflammatory and/or degenerative conditions using the combination of active ingredients as herein described.

The present invention provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof and (ii) a penetration enhancer, and optionally including tannic acid, or an analogue or derivative thereof. The present invention also provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof, and (ii) tannic acid, or an analogue or derivative thereof, optionally including a penetration enhancer. Also provided are kits and methods of prophylactic or therapeutic treatment of inflammatory and/or degenerative conditions using the combination of active ingredients as herein described.

The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.